BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00388492|
Recruitment Status : Unknown
Verified October 2006 by Bellos, Nicholaos C., M.D..
Recruitment status was: Not yet recruiting
First Posted : October 16, 2006
Last Update Posted : January 11, 2007
The goal of this study is to evaluate the proportion of subjects both antiretroviral experienced and virologically suppressed on lopinavir/ritonavir (LPV/r)400/100mg twice daily who maintain viral suppression after switching to lopinavir/ritonavir (LPV/r)800/200mg once daily.
The hypothesis for this study is that the majority of subjects will remain virologically suppressed with once daily dosing versus twice daily dosing and therefore quality of life will be improved with the once daily dosing of lopinavir/ritonavir (LPV/r)800/200mg.
|Condition or disease|
|Study Type :||Observational|
|Enrollment :||45 participants|
|Observational Model:||Defined Population|
|Official Title:||BLADE: "A Comparison of Once Daily LPV/r to LPV/r BID in HIV-Infected Virologically Controlled Antiretroviral Experienced Subjects"|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388492
|Contact: Keri Neuling||214-828-4702 ext firstname.lastname@example.org|
|Contact: Denise Ramos||214-828-4702 ext email@example.com|
|Principal Investigator:||Nicholaos C. Bellos, MD||Nicholaos C. Bellos, MD|